Skip to main content

Galapagos Division to Make Cell-based Assays for Dart Drug Program

NEW YORK (GenomeWeb News) – Galapagos’ service division, BioFocus DPI, will make cell-based assays for Dart Neuroscience, which will use them in its drug discovery programs for brain disorders, Galapagos said today.
 
The three-year collaboration is potentially worth €4.1 million ($5.4 million) to Galapagos, the Mechelen, Belgium-based firm said.
 
In addition to providing the assays, BioFocus will perform high-throughput screening and hit expansion using its compound collections. It also will provide compound management for Dart over the three-year period.
 
San Diego-based Dart is privately held and was founded earlier this year.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.